P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy375.057
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Potential Mechanisms for Thrombocytopenia Development With Trastuzumab Emtansine (T-Dm1)

Clinical Cancer Research
Cancer ResearchOncology
2014English

T-Dm1 Reduces HER2+ Breast Cancer Recurrence

Cancer Discovery
Oncology
2018English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)

Breast Cancer Research
Cancer ResearchOncology
2019English

Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer

The Open Breast Cancer Journal
2009English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy